Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

4.460 +0.040 (+0.90%)
Streaming Delayed Price Updated: 12:12 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100,991
Open 4.450
Bid (Size) 4.450 (500)
Ask (Size) 4.470 (300)
Prev. Close 4.420
Today's Range 4.385 - 4.600
52wk Range 2.780 - 6.450
Shares Outstanding 83,399,377
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Q1 Earnings Call Highlights ↗
Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no... 
Via MarketBeat
Topics Earnings

Performance

YTD
+28.2%
+28.2%
1 Month
-16.8%
-16.8%
3 Month
-2.8%
-2.8%
6 Month
+49.7%
+49.7%
1 Year
+51.2%
+51.2%

More News

Read More
Atea Pharmaceuticals (NASDAQ:AVIR) Q1 Loss Narrows as HCV and HEV Pipeline Catalysts Loom ↗
Via Chartmill
News headline image
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals (NASDAQ:AVIR) Reports Q4 2025 Results as HCV and HEV Pipeline Advance ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
Via Benzinga
News headline image
Atea Pharma (AVIR) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. ↗
Via The Motley Fool
News headline image
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharma (AVIR) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Atea Pharmaceuticals Inc (NASDAQ:AVIR) Reports Q3 2025 Financial Results and Business Update ↗
Via Chartmill
News headline image
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Earnings Preview ↗
Via Benzinga
News headline image
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Atea Pharmaceuticals, Inc. - common stock publicly traded?
Yes, Atea Pharmaceuticals, Inc. - common stock is publicly traded.
What exchange does Atea Pharmaceuticals, Inc. - common stock trade on?
Atea Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Atea Pharmaceuticals, Inc. - common stock?
The ticker symbol for Atea Pharmaceuticals, Inc. - common stock is AVIR on the Nasdaq Stock Market
What is the current price of Atea Pharmaceuticals, Inc. - common stock?
The current price of Atea Pharmaceuticals, Inc. - common stock is 4.460
When was Atea Pharmaceuticals, Inc. - common stock last traded?
The last trade of Atea Pharmaceuticals, Inc. - common stock was at 05/26/26 12:12 PM ET
What is the market capitalization of Atea Pharmaceuticals, Inc. - common stock?
The market capitalization of Atea Pharmaceuticals, Inc. - common stock is 371.96M
How many shares of Atea Pharmaceuticals, Inc. - common stock are outstanding?
Atea Pharmaceuticals, Inc. - common stock has 372M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.